The oral S1P1 and S1P5 receptor agonist drug – now given the trade name Zeposia – was billed as one of the top 2020 drug launches to watch by Clarivate last month, before the COVID-19 outbreak ...

Results are due next year. Cenerimod, meanwhile, is a selective S1P1 receptor modulator in two phase 3 trials – OPUS-1 and OPUS-2 – that are comparing the drug to placebo when the drug is ...